Exscientia Ltd ADR (EXAI)

Currency in USD
4.840
0.000(0.00%)
Closed·
Showing Exscientia ADR historical data. For real-time data please try another search
Day's Range
4.4854.850
52 wk Range
3.8006.875
Key Statistics
Prev. Close
4.84
Open
4.63
Day's Range
4.485-4.85
52 wk Range
3.8-6.875
Volume
-
Average Volume (3m)
712.99K
1-Year Change
4.31%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Exscientia Ltd ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Exscientia Ltd ADR Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company’s lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité – Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom. As of November 20, 2024, Exscientia plc operates as a subsidiary of Recursion Pharmaceuticals, Inc..

Exscientia Ltd ADR SWOT Analysis


AI Biotech Merge
Exscientia's merger with Recursion Pharma aims to create an AI-driven biotech powerhouse, potentially revolutionizing drug discovery and development processes
Pipeline Progress
Key clinical programs, including CDK7 and MALT1 inhibitors, are advancing with potential data readouts that could significantly impact company valuation
Financial Outlook
Extended cash runway into 2027 provides stability, but ongoing losses and negative EPS forecasts highlight challenges faced by clinical-stage biotech firms
Market Dynamics
Analysts' price targets range from $5 to $10, reflecting mixed views on Exscientia's potential amid fierce competition and regulatory challenges in the biotech secto
Read full SWOT analysis

Exscientia Ltd ADR Earnings Call Summary for Q4/2023

  • Exscientia reports $463M cash, runway into 2026; advances in AI-driven drug discovery, focusing on oncology partnerships
  • Launched automation suite to enhance ML models, reduce costs; first to integrate AI-led drug design with automated experimentation
  • CDK7 inhibitor in Phase I/II trial; LSD1 inhibitor to enter human studies in H2 2024; seeking additional partnerships
  • Anticipates increased milestones from Sanofi collaboration in next 18-36 months; open to new biopharma and tech partnerships
Last Updated: 21/03/2024, 23:50
Read Full Transcript

Earnings

Latest Release
Mar 20, 2025
EPS / Forecast
-0.40 / -0.0563
Revenue / Forecast
4.93M / 59.84M
EPS Revisions
Last 90 days

EXAI Income Statement

People Also Watch

20.385
JOBY
+18.79%
140.05
ARM
+1.80%
68.56
ALB
+0.98%
176.77
AMD
+2.95%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.